Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Ponsse manufactures its 17,000th forest machine

The 17,000th PONSSE forest machine has rolled off the production line in Vieremä. The milestone machine, a PONSSE Elk built in mid-August, will start its career in the sure hands of Kuusmoto Oy. “It is a special privilege to hand over the 17,000th PONSSE machine to the Finnish Kuusmoto Oy. I wish to thank Kuusmoto for their trust and fantastic cooperation as we continue our journey together,” says Sales, Service and Marketing Director Marko Mattila.Founded in 2014 and hailing from Posio in Finland, Kuusmoto Oy currently employs 17 people. They operate in seven municipalities in

Study Reveals: Potential Launch of Amazon Pharmacy Has High Effects on Pharmacy Market in UK

The British are ready for Amazon Pharmacy, the company can rely on its customer intimacy and awareness. More than 40 percent of regular Amazon customers would use the mail-order giant’s pharmaceutical offer.London, August 19, 2021 – With Amazon already a very strong distribution channel for OTC products in the UK, it is only a matter of time before Amazon leverages its already registered trademark and also launches Amazon Pharmacy, which will have an even greater impact on the market. Study* results by Simon-Kucher & Partners, a global strategy and marketing consulting firm, reveal that

SMART WIRES TECHNOLOGY LTD, Q2 2021 INTERIM REPORT

Smart Wires Technology Ltd (“Smart Wires”) presents its Q2 2021 Interim Report at 15:00 CEST on 19[ ]August 2021 via audiocast teleconference at the following link: https://tv.streamfabriken.com/smart-wires-q2-2021. Teleconference: Dial-in number SE: +46856642707 UK: +443333009264 US: +1 6319131422, PIN: 26807678#The Company’s Key Business Events and Metrics for Q2 2021 include: ·First trading day on the Nasdaq First North Growth Market on 18 May 2021 · Qualified pipeline increased to $2.3 billion · Revenue of $10.2 million, +445% · Gross loss of $0.5 million, +85%

The Integration of Wulff and Staples Finland proceeds

STOCK EXCHANGE RELEASE, INSIDER INFORMATION  AUGUST 19, 2021 AT 1.00 P.M. Wulff, an expert in work environment products and services, is implementing an organizational reform in their Contract Customer Segment in Finland. The services and products of Staples Finland Oy (now Wulff Solutions Oy), which was acquired for the Group in May, complement Wulff's range nicely. Customers, personnel and partners find it valuable that the company's operations will be developed in the future as part of the operations of the domestic market leader. “The acquisition of Staples will support the

Mandatory notification of trade – primary insider

The following primary insider in Multiconsult ASA has purchased shares in Multiconsult ASA: Bård Mikkelsen, Chairman of the Board in Multiconsult ASA, has on 19 August 2021 purchased 3 000 shares in Multiconsult ASA at an average price of NOK 179.6993 per share and will after the transaction hold 17 933 shares in Multiconsult ASA.For further information, please contact:    Investor relations:      Pål-Sverre Jørgensen, Group Treasurer & Investor Relations Officer      Phone: +47 416 11 161      E-mail: ir@multiconsult.no      Media:      Gaute Christensen, VP

Cantargia expands CIRIFOUR trial after successful completion of recruitment in the pembrolizumab combination arm

Cantargia AB today announced that the last patient in the initial treatment arm of the phase Ib clinical study CIRIFOUR has started treatment. A total of 15 patients have so far been recruited to this study, which evaluates nadunolimab (CAN04) in combination with Keytruda® (pembrolizumab), and preliminary data indicate a good safety profile. The CIRIFOUR study protocol will now be expanded to include the next combination therapy arm where CAN04 is evaluated with pembrolizumab and platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC).The interleukin-1 receptor

Professor Olle Hernell has received the Macy György award

Press release: Umeå, 19 August, 2021. Professor Olle Hernell that is co-founder and board member of Lipum has been honored with the Macy György award 2021 for his research in human milk and lactation.For almost 50 years Professor of Pediatrics Olle Hernell and his group at Umeå University have been studying breast milk and its importance for nutrition of newborns during early infancy with focus on the bioactive protein that is now known as bile salt-stimulated lipase (BSSL). Hernell and his team also revealed that BSSL plays a role in inflammation and is present in human granulocytes, a

HusCompagniet’s holding of treasury shares

Company announcement 18/2021 With reference to company announcement no. 15 dated 19 August 2021, HusCompagniet A/S (the “Company”) has increased its holding of treasury shares and now holds 1,683,058 shares, corresponding to 8.4% of the total share capital and voting rights of the Company. For additional information, please contact: HusCompagniet Cristina Rønde Hefting, Head of IR & Press                                               +45 51 96 23 14 About HusCompagniet HusCompagniet is a leading provider of single-family detached houses in Denmark. The company also builds

Major shareholder announcement

Company announcement 17/2021 In accordance with section 30 of the Capital Markets Act, HusCompagniet A/S (the “Company”) hereby announces that EQT VI Limited has notified the Company that EQT VI Limited, through Diego Holding Guernsey Limited, has sold its total holding of shares in the Company and no longer holds shares or voting rights in the Company. For additional information, please contact: HusCompagniet Cristina Rønde Hefting, Head of IR & Press                                               +45 51 96 23 14 About HusCompagniet HusCompagniet is a leading provider of

Today CS MEDICA will attend a webinar at Nordnet Live and informs on Biostock article

Today, August 19[th], 2021, CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) announces CEO Lone Henriksen and CFO Gitte Henriksen will present the Company and talk about the upcoming listing at the webinar Nordnet Live, today at 15:30. Further, Biostock has released an article presenting the Company and the expansion across Europe.Webinar Nordnet LiveNordnet Live will today, on August 19[th] at 15.30, host a webinar and receive a visit by CS MEDICA’s CEO Lone Henriksen and CFO Gitte Henriksen, where they will present the Company and talk about CS MEDICA's upcoming IPO. There will be an

Revenue in the second quarter amounted to 195.8 MSEK, representing growth of 7.3%

Revenue in the second quarter amounted to 195.8 (182.4) MSEK, representing a growth of 7.3%. Support and maintenance fees constitute the largest share of the revenue. License revenue and Professional Services revenue are attributable to the development of the existing product as well as the Sussa project.Adjusted EBITDA in the second quarter amounted to 22.7 (50.6) MSEK resulting in an adjusted EBITDA margin of 11.6 (27.7) %. Employee related expenses amounted to 141.2 (110.2) MSEK, corresponding to an increase of 28.1%. The number of full-time employees rose to 765 in the second quarter,

Klaria Interim Report Q2 2021

Klaria Interim Report Q2 2021Summary of the interim report  Positive results for the bioequivalence registration study with Sumatriptan Alginate Film SECOND QUARTER OF 2021 · Net sales amounted to 0.0 MSEK (0.0 MSEK · Other income amounted to 0.0 MSEK (1.1 MSEK) · R&D costs for the period amounted to 11.5 MSEK (9.2 MSEK) · Profit after tax amounted to -15.9 MSEK (-10.1 MSEK) · Earnings per share for the quarter amounted to -0.31 SEK (-0.24 SEK) · Cash flow from operating activities amounted to -13.5 MSEK (-13.4 MSEK) · Cash and cash equivalents on the balance

Correction: ExpreS2ion announces financial results for the second quarter of 2021

Hørsholm, Denmark, August 19, 2021 – This morning ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announced its second quarter financial results for 2021. Some figures were reported incorrectly, specifically the operating income and H1 2020 earnings per share figures reported below in the press release, which are now highlighted in bold. These figures were also incorrect on page 13 of the Q2 report. The corrected figures are reflected in this revised press release and in the attached report, which is also available on ExpreS2ion's website (www.expres2ionbio.com).CEO Bent U. Frandsen comments

Katarina Grönwall and Sofia Brax new members of OX2 Management Team

Katarina Grönwall will take on the position as Chief Communications Officer and Sofia Brax as Chief People Officer.During 2021 OX2 has taken further steps to become a leading provider of wind and solar power farms. The company has been listed on the Nasdaq First North Premier Growth Market, expanded its portfolio and added new markets. The company has now appointed two new members to the management team that will be key to support this growth. Katarina Grönwall will take on the position as Chief Communications Officer. Katarina has previously been Senior Vice President Communications at

HC Andersen Capital initiates research on Risk Intelligence A/S

HC Andersen Capital has on behalf of Risk Intelligence A/S today initiated coverage with its first report.CEO Hans Tino Hansen says:“Our ambition with this coverage is to offer existing as well as future shareholders the possibility to get a deeper understanding of Risk Intelligence, our market and our opportunities.” About HC Andersen capital:HC Andersen Capital assists companies that aspire for a higher visibility in the market among both private and institutional investors Analyst and contact information: Kasper Lihn, kasper@hcandersencapital.dk Link to the report: HC

Audientes Half-year Report: Ven™ available for pre-ordering

Today, Audientes A/S’ financial results for the period April 1 – June 30, 2021 were approved by the Board of Directors, and the company has now published its interim report for Q2 and H1 2021.Company announcement no. 8-2021 August 19, 2021 During Q2 2021, Audientes accelerated its market development and announced its initial commercial partners, while continuing the completion of its product in the lead-up to the product launch and sales in H2 2021. Steen Thygesen, CEO Audientes A/S, comments: “We are very satisfied with the results in H1 2021 and have high expectations for H2

Aker Carbon Capture ASA: New share capital registered

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Reference is made to the stock exchange announcements by Aker Carbon Capture ASA (the “Company”) published on 12 August 2021 regarding a successfully completed private placement of 38,181,818 new ordinary shares (the “New Shares”) in the

Calmark receives order from Egypt

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Egypt, Enox Pharma AB, covering the Calmark Neo platform and bilirubin tests. The economic value of today's order is of minor importance, but it is important from a launch perspective.As previously disclosed, an exclusive distributor agreement has been signed with the company Enox Pharma AB regarding marketing and sales of Calmark's products in the countries Egypt, Iraq, Bahrain, Saudi Arabia and the United Arab Emirates.  “I am happy for the order which shows that our distributor now

Coloreel appoints new CEO

In alignment with Coloreels extensive and international growth strategies a new CEO has been appointed, Torbjörn Bäck. With previous experience from various senior positions at companies such as Camfil, Nederman and IBM. Torbjörn will steer Coloreel and its unique patented technology for digital dyeing of textile thread on-demand into a prosperous growth journey.The Board of Directors of Coloreel has appointed Torbjörn Bäck as CEO starting Aug 9, 2021. He will succeed Mattias Nordin who will transition to a new roles within Coloreel as Senior Vice President Business Development. “We like to

Seven-layer silage barrier film and films up to 39 meters wide

Michelstadt/Germany, August 19, 2021 – RKW Agri launches Polydress® FarmGuard, a next-generation e7 silage barrier film that offers, among other features, a significantly improved oxygen barrier to protect silage and easier handling. No more need for a vacuum film, saving farmers time, effort, and material, and also reducing waste. All of which means built-in sustainability.The new 100 µm Polydress® FarmGuard silage barrier film is up to 100 times more effective as an oxygen barrier than standard silage films. Moreover, it is easy to handle thanks to its extreme strength, as demonstrated by

Techstep ASA: Q2 2021 results

Highlights Q2 2021 · Revenue was NOK 325 million, up 36% from NOK 238 million in the second quarter of 2020 · Gross profit was NOK 114 million, up 46% from NOK 78 million in the second quarter of 2020 · EBITDA adjusted was NOK 13 million in the quarter vs NOK 17 million in the second quarter of 2020, a 23% decline · ARR reported increased to NOK 64 million, up 73% from NOK 37 million in the second quarter of 2020. Proforma ARR including Famoc was NOK 93 million, up 149% · Signed 6 new managed mobility service contracts, with an estimated value of NOK 77 million and ~7,300

Invitation to Q2 2021 webcast

Zalaris ASA will release its second quarter 2021 results on Thursday 26 August 2021.Zalaris will host a webcast for all shareholders and interested parties on 26 August at 08:30 CET. There will be a Q&A session following the management presentation. Link to webcast will be available on ir.zalaris.com.   Contact: Gunnar Manum, CFOMobil: +47 95 17 91 90 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

There are no items matching the current filter
There are no more items matching the current filter
Back to top